Related Experiment Video
Updated: Jun 20, 2026
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
The IASLC uncertain resection, general overview, current evidence, and future prospects: a systematic review and
Mingming Hu1,2, Xiaomi Li3, Maike Zheng3
1Department of Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Background:
Introduced by the International Association for the Study of Lung Cancer (IASLC) in 2005, uncertain resection (Run) categorizes a new subclass of residual tumor. Despite several studies, the prognostic significance of Run in operable non-small cell lung cancer (NSCLC) remains unclear.
Objectives:
This study aimed to investigate the prognostic influence of Run in operable NSCLC, focusing on the impact of the four elements that comprise R descriptors on patient survival.
Design:
A systematic review and meta-analysis were conducted to synthesize data from relevant clinical studies.
Methods:
We developed search strategies to identify relevant clinical studies across databases including PubMed, Embase, Cochrane Library, Web of Science, CNKI, and Wanfang up to June 2024. Quantitative analysis was performed with Stata 15 to investigate the prognostic influence of Run, the extent of mediastinal lymph node removal, and the highest mediastinal lymph node involvement (HMLI). We also summarized the main findings from studies on pleural lavage cytology (PLC) and carcinoma in situ in operable NSCLC.
Results:
Compared to complete resection, Run-associated patients exhibited inferior 5-year overall survival (OS) and disease-free survival (DFS; risk ratio (RR) = 1.31, 95% confidence interval (CI) 1.19-1.44; RR = 1.43, 95% CI 1.28-1.60). Limited lymphadenectomy (L-LA) in cI stage showed similar survival benefit (OS, RR = 0.97, 95% CI 0.90-1.06; DFS, RR = 1.06, 95% CI 0.97-1.15), in contrast with systematic lymph node dissection (SLND). For pN2-III patients, HMLI indicated poorer OS (hazard ratio (HR) = 1.22, 95% CI 1.14-1.31) and DFS (HR = 1.25, 95% CI 1.14-1.36).
Conclusion:
IASLC's residual tumor classification correlated with significant survival differences. Compared with R0, Run was associated with inferior 5-year OS and DFS. L-LA seemed to provide equivalent survival benefits, in contrast to SLND. For patients with low invasiveness in stage cI, L-LA could be considered as a preferred option. HMLI predicts poorer survival in pN2-III patients, and positive PLC significantly worsened long-term survival in operable NSCLC, particularly at early stage.
More Related Videos
Related Concept Videos
01:20Inductively Coupled Plasma-Mass Spectrometry (ICP-MS): Interferences
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...